Status:
COMPLETED
Thorough QT Study of Nelfinavir
Lead Sponsor:
Pfizer
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
To assess if nelfinavir has any clinically meaninful effect on cardiac function, namely ECG evaluation
Eligibility Criteria
Inclusion
- Healthy male and female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of approximately 18 to 30 kg/m2.
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00312182
Start Date
March 1 2006
End Date
June 1 2006
Last Update
April 10 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511-5473
2
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48105
3
Pfizer Investigational Site
Brussels, Belgium, B-1070
4
Pfizer Investigational Site
Singapore, Singapore, 169608